Drug Type Small molecule drug |
Synonyms + [1] |
Target |
Mechanism MEK1 inhibitors(Dual specificity mitogen-activated protein kinase kinase 1 inhibitors), MEK2 inhibitors(Dual specificity mitogen-activated protein kinase kinase 2 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization ![]() |
Active Organization ![]() |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (12 Mar 2024), |
RegulationConditional marketing approval (CN), Special Review Project (CN), Priority Review (CN) |
Molecular FormulaC16H12F2IN3O3S |
InChIKeyUFZJUVFSSINETF-UHFFFAOYSA-N |
CAS Registry1801756-06-8 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
NRAS Mutant Melanoma | CN | ![]() | 12 Mar 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
BRAF V600E mutant Colorectal Cancer | Phase 3 | CN | ![]() | 16 Oct 2023 |
KRAS mutant Non-small Cell Lung Cancer | Phase 3 | CN | ![]() | 21 May 2020 |
BRAF V600E mutant Non-small Cell Lung Cancer | Phase 2 | - | ![]() | 24 Sep 2023 |
NF1 mutant Plexiform Neurofibroma | Phase 2 | CN | ![]() | 01 Nov 2021 |
Neurofibromatosis 1 | Phase 2 | CN | ![]() | 18 Oct 2021 |
BRAF mutation positive Melanoma | Phase 2 | CN | ![]() | 23 Sep 2021 |
RAS/RAF mutation Solid Tumors | Phase 1 | CN | ![]() | 17 Aug 2020 |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | ![]() | 01 Jul 2018 |
BRAF Mutation Non-small Cell Lung Cancer | IND Approval | CN | ![]() | 26 Jun 2023 |
Phase 2 | BRAF V600 mutation-positive Melanoma BRAF V600E-mutant | 17 | (vhnbjlhrzo) = otcemnpbdi rppltfrkbp (iqoxmbueal, 44.0% - 89.7) View more | Positive | 24 May 2024 | ||
Phase 2 | 100 | (twgdwzbttz) = zpszqvsffl xteypvbgfy (exatzdboqk, 26.3% - 46.3%) View more | Positive | 24 May 2024 | |||
NCT03781219 (ESMO2023) Manual | Phase 1 | Advanced Malignant Solid Neoplasm BRAF V600 mutation | 72 | (vkukjgfxea) = The most common AE were CK elevation, anemia and rash which were predominantly grade 1/2. dopewjdlvz (euijujrfvj ) | Positive | 23 Oct 2023 | |
(NSCLC) | |||||||
NCT05217303 (ASCO2023) Manual | Phase 2 | NRAS Mutant Melanoma NRAS Mutation | 100 | (mpjsbcznxm) = pmettwdwhm cqvqebnqzk (wxnxhzwgwn, 25.3 - 45.2) View more | Positive | 26 May 2023 | |
Phase 1 | 42 | (xelcwbbnot) = gvrgiyhvgh nkufntczfi (jbjnsbavxz ) View more | - | 04 Jan 2023 | |||
Phase 1/2 | 33 | (mpxfoqkdxf) = the most common drug-related AEs were aspartate aminotransferase vpqpxxtgbq (utwacdhlla ) View more | Positive | 25 May 2020 |